Regulatory news:

ACTICOR BIOTECH (FR0014005OJ5 ALACT), a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on the current receivership procedure.

In order to allow the Company to continue its search for new investors or partners to support its new development plan in STEMI (ST-Elevation Myocardial Infarction), the receiver granted an extension in mid-October 2024 until Tuesday 5 November 2024 for the call for tenders published on September 13, for a continuation or transfer plan.

To date, the receiver has not received any buyer proposals. The Company is therefore continuing its search for a solution to support the development of glenzocimab in STEMI and the 6-month observation period beginning on August 6, 2024 is underway.

As a reminder, on August 6, 2024, the Paris Commercial Court ordered the opening of a judicial recovery procedure. The purpose of this procedure is to allow the Company to evaluate all the options available to it to continue its development, the development of its product, glenzocimab, and its search for financing and partners. As already mentioned, this procedure will also allow the Company to finance its operations until January 2025.

The Company will continue to keep the market informed of developments in the ongoing receivership procedure and calls on investors to closely monitor future communications regarding its development.

About ACTICOR BIOTECH

ACTICOR BIOTECH, a clinical-stage biopharmaceutical company founded in 2013 based on work at INSERM, is developing glenzocimab, a humanized monoclonal antibody fragment (fab) targeting the platelet GPVI receptor for the treatment of cardiovascular emergencies and acute thrombotic diseases .

The main clinical indication evaluated is acute ischemic stroke, due to the strong need for safer treatments, especially those that do not increase the hemorrhagic risk, and its high incidence. In three international clinical trials involving more than 600 stroke patients, no significant impact on neurological improvement (mRS score at 3 months) was demonstrated, with the exception of a subpopulation of patients. with intracerebral hemorrhage, where mortality was significantly reduced by a factor of 3 (p = 0.035) (Mazighi et al. 2024).

LIBERATE, a Phase 2 clinical trial in the acute phase of myocardial infarction (STEMI), is currently recruiting through an academic partnership with the University of Birmingham (UK). This study aims to demonstrate the effectiveness of glenzocimab in reducing myocardial infarct size, a critical factor for long-term heart function.

In total, more than 800 subjects were included in the clinical trials, of which more than 400 were exposed to glenzocimab without safety concerns.

The use of glenzocimab in thrombotic diseases is covered by 3 patent families, with an expiry date in 2036 for the first family. ACTICOR BIOTECH also has the right to develop a biomarker for stroke patients.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 ALACT).

For more information, visit: www.acticor-biotech.com

Disclaimer

This press release contains forward-looking statements regarding Acticor Biotech and its business. Acticor Biotech believes that these forward-looking statements are based on reasonable assumptions. However, there can be no assurance that the expectations expressed in these forward-looking statements will prove to be correct, as they are subject to risks, including those described in the Universal Registration Document filed with the Autorité des marchés financiers on July 9. , 2024, and changes in economic conditions, financial markets and the markets in which Acticor Biotech operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Acticor Biotech or that Acticor Biotech does not currently consider to be material. The occurrence of any or all of these risks could cause Acticor Biotech’s actual results, financial condition, performance or achievements to differ materially from those expressed in the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241105824773/en/

Contacts:

ACTICOR BIOTECH
Gilles AVENARD, MD

CEO and Founder

[email protected]

Sophie BINAY, PhD

Managing Director and CSO

[email protected]

NewCap
Mathilde BOHIN

Investor Relations

[email protected]
T. : +33 (0)1 44 71 94 95

NewCap
Arthur ROUILLE

Media Relations

[email protected]
T. : +33 (0)1 44 71 00 15